Table 6. Costs, outcome and cost effectiveness.
| Costs and outcomes | Base case | Scenario 1 | Scenario 2 | Scenario 3 |
|---|---|---|---|---|
| HD:CAPD ratio | 60:40 | 55:45 | 50:50 | 70:30 |
| Undiscounted | ||||
| Projected cost, RM | 313,412 | 308,032 | 307,014 | 311,086 |
| Total LYs | 8.005 | 7.910 | 7.902 | 7.933 |
| Total QALYs | 7.113 | 7.037 | 7.041 | 7.025 |
| Discounted (3%) | ||||
| Projected cost, RM | 94,425 | 93,517 | 93,236 | 94,361 |
| LYs | 2.417 | 2.407 | 2.407 | 2.410 |
| QALYs | 2.150 | 2.145 | 2.148 | 2.136 |
| Cost effectiveness | ||||
| Cost per LY (discounted) | 39,074 | 38,844 | 38,740 | 39,156 |
| Cost per QALY (discounted) | 43,919 | 43,591 | 43,399 | 44,172 |
| Cost per LY (undiscounted) | 39,151 | 38,943 | 38,852 | 39,214 |
| Cost per QALY (undiscounted) | 44,059 | 43,774 | 43,606 | 44,281 |
| ICER | ||||
| Per LY (discounted) | 120,160 | 355,207* | - | 355,207* |
| Per QALY (discounted) | 734,979 | -92,909* | - | -92,909* |
| Per LY (undiscounted) | 62,090 | 132,108* | - | 132,108* |
| Per QALY (undiscounted) | 87,864 | -264,922* | - | -264,922* |
ICER-incremental cost effectiveness ratio, QALY-quality-adjusted life year, LY-life Year
*”dominated” (worse outcomes, higher costs)